Successful Installation of World’s First 1.2 GHz NMR System Enables Novel Functional Structural Biology Research
May 04 2020 - 07:00AM
Business Wire
CERM of University of Florence, Italy
Accepts Bruker 1.2 GHz NMR System
Bruker Corporation (Nasdaq: BRKR) today announced the successful
installation and customer acceptance of the world’s first
Avance™ NEO 1.2 GHz NMR system at the CERM
(www.cerm.unifi.it) of the University of Florence. CERM is an
Italian center of the European research infrastructure in
structural biology, called Instruct-ERIC.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200504005189/en/
Acceptance of 1.2 GHz NMR at CERM, U. of
Florence: Professor Lucia Banci and Bruker engineer Joerg Tischler
(Photo: Business Wire)
Thanks to the tireless efforts and support by our customers and
partners at CERM, as well as by our field service engineers, Bruker
was able to carry out this first ultra-high field NMR 1.2 GHz
installation while adhering to COVID-19 safety guidelines.
Following the acceptance of the world’s first 1.1 GHz NMR at the
St. Jude Children’s Research Hospital (www.stjude.org) in late
2019, this achievement marks the second successful customer
installation of a Bruker GHz-class NMR system with a novel HTS/LTS
hybrid magnet design (explained below).
This new 1.2 GHz NMR system will enable CERM to perform novel
research in functional structural biology of proteins and protein
complexes. The CERM research focuses on the structures, dynamics
and functions of important globular proteins, membrane proteins and
protein complexes. Ultra-high field (UHF) NMR is unique in its
capabilities to study “difficult” protein systems and biological
questions. These include the high-resolution structural and dynamic
characterization of proteins, and their interactions in human
living cells near physiological conditions. GHz-class NMR also
enables improved research on intrinsically disordered proteins
(IDPs) that make up 30%-50% of the human proteome. IDPs are
implicated in many instances of disease biology.
Professors Lucia Banci and Claudio Luchinat at the CERM of
University of Florence, stated: “We are thrilled to have the
world’s first 1.2 GHz NMR spectrometer successfully installed in
our lab. We are looking forward to putting the instrument to use in
our research on the structures and function of proteins linked to
neurodegenerative diseases, such as Alzheimer's and Parkinson's
Diseases, as well as in cancer and viral protein structure and
functional research. Right now, we are actively working on
SARS-CoV-2 proteins, and we will soon record the first 1.2 GHz NMR
spectra of a protein from this coronavirus!”
Dr. Falko Busse, Bruker BioSpin's Group President, stated: “I am
deeply grateful to our customers for their support and flexibility
during the installation phase, and we look forward to their
enabling research in functional structural biology and IDPs at 1.2
GHz. We are very excited that the installation of the world’s first
1.2 GHz NMR spectrometer in Florence was successful and look
forward to moving to the next phase of our UHF NMR program with
additional customer deliveries.”
Bruker's unique 1.1 and 1.2 GHz NMR magnets utilize a novel
hybrid technology with advanced high-temperature superconductors
(HTS) in the inner sections, and low-temperature metallic
superconductors (LTS) in the outer sections. The Ascend™ 1.1
and 1.2 GHz magnets are stable, homogenous, standard-bore (54 mm)
magnets that meet the requirements of high-resolution and
solid-state NMR. Bruker’s Avance™ NEO 1.1 and 1.2 GHz
spectrometers offer different ultra-high field CryoProbes™ for
solution-state NMR and fast-spinning MAS biological solid-state
probes.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200504005189/en/
Investor Contact: Investor Contact: Miroslava Minkova
Director, Investor Relations & Corporate Development T: +1
(978) 663-3660 x1479 E: Investor.Relations@bruker.com
Customer and Media Contact: Thorsten Thiel, Ph.D. VP of
Group Marketing Bruker BioSpin T: +49 (721) 5161–6500 E:
thorsten.thiel@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Mar 2023 to Mar 2024